Ana Viu

Liver stiffness dynamics in European populations (LiverScreen): a longitudinal, multicentre, prospective, population-based cohort study

Jesse Pustjens, K. Bech, Guillem Pera, Laurens A. van Kleef et autres

nl, dk, es, ca (code pays fourni par la source)

Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study

Miquel Serra‐Burriel, Adrià Juanola, Maja Thiele, Isabel Graupera et autres

ch, es, dk, hr, it, nl, de, fr, gb, us, no, hk (code pays fourni par la source)

LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries

Isabel Graupera, Maja Thiele, Ann T., Miquel Serra‐Burriel et autres

es, dk, ch, nl, hr, de, fr, it, gb, be, us, no (code pays fourni par la source)

Follow‐up evaluation of patients with liver test abnormalities detected during SARS‐CoV2 infection

Lidia Canillas, Teresa Broquetas, J.A. Carrión, Giulia Pagano et autres

es (code pays fourni par la source)

On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty

Teresa Broquetas, Juan-Jose Hernandez, Montserrat Garcı́a-Retortillo, Lidia Canillas et autres

es (code pays fourni par la source)

Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients

Teresa Broquetas, Montserrat Garcı́a-Retortillo, Miquel Micó, Lidia Canillas et autres

es (code pays fourni par la source)

Efficacy and safety of treatment interruption in patients with HBeAg negative chronic hepatitis B

Teresa Broquetas, Miquel Micó, Montserrat Garcı́a-Retortillo, Nuria Cañete Hidalgo et autres

Expansion of a multidisciplinary support program for patients with addictions and hepatitis C: strategies for an effective approach

Montserrat Garcı́a-Retortillo, Nuria Cañete Hidalgo, Francina Fonseca, Daniel Roca et autres

SAT-231-Impact of the HCV cure with DAAs in the use of concomitant medication and the serum lipid profile: Follow-up data one year after the SVR12

Marc Batlle, Inés Monge‐Escartín, Xavier Durán, Ana Viu et autres

THU-124-Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C)

Marc Puigvehí, Agustı́n Albillos, Ana Viu, Manuel Hernández‐Guerra et autres

Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild‐moderate fibrosis: Results from a real‐world cohort

Marc Puigvehí, B. de Cuenca, Ana Viu, M. Diago et autres

es (code pays fourni par la source)